Biocept Announces Panel Presentation at Cantor Fitzgerald Healthcare Conference
"We appreciate Cantor Fitzgerald's focus on the promising field of
liquid biopsy and are delighted to participate on this panel," said Mr.
Nall. "We see a clear benefit of using a simple blood draw to help
physicians personalize their patients' treatment by monitoring disease
status to adjust treatment when necessary. At
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to our impact on the field of
personalized medicine and diagnostic strategies, and planned future
offerings, such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to numerous
risk factors as set forth in our
View source version on businesswire.com: http://www.businesswire.com/news/home/20150706005238/en/
Investor Contact:
LHA
jcain@lhai.com
Source:
News Provided by Acquire Media